NCT01873833: A trial that was reported late by University of Southern California
This trial has reported, although it was 254 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01873833 |
|---|---|
| Title | Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 29, 2013 |
| Completion date | March 2, 2021 |
| Required reporting date | March 2, 2022, midnight |
| Actual reporting date | Nov. 11, 2022 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 254 |